{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T05:03:22Z","timestamp":1770527002468,"version":"3.49.0"},"reference-count":128,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2012]]},"DOI":"10.5551\/jat.12450","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T09:23:02Z","timestamp":1337678582000},"page":"693-704","source":"Crossref","is-referenced-by-count":20,"title":["Anti-Atherosclerotic Potential of Dihydropyridine Calcium Channel Blockers"],"prefix":"10.5551","volume":"19","author":[{"given":"Norio","family":"Ishii","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Peeters A, Mamun AA, Willekens F, Bonneux L: A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J, 2002; 23: 458-466","DOI":"10.1053\/euhj.2001.2838"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126","DOI":"10.1056\/NEJM199901143400207"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Libby P: Molecular bases of the acute coronary syndromes. Circulation, 1995; 91: 2844-2850","DOI":"10.1161\/01.CIR.91.11.2844"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (2). New Engl J Med, 1992; 326: 310-318","DOI":"10.1056\/NEJM199201303260506"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Henry PD: Atherosclerosis, calcium, and calcium antagonists. Circulation, 1985; 72: 456-459","DOI":"10.1161\/01.CIR.72.3.456"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) The ENCORE Investigators: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation, 2003; 107: 422-428","DOI":"10.1161\/01.CIR.0000046488.52939.BF"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 2006; 113: 1213-1225","DOI":"10.1161\/CIRCULATIONAHA.105.595496"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 2000; 102: 1503-1510","DOI":"10.1161\/01.CIR.102.13.1503"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P; European Lacidipine Study on Atherosclerosis investigators: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation, 2002; 106: 2422-2427","DOI":"10.1161\/01.CIR.0000039288.86470.DD"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Zhang X, Hintze TH: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation, 1998; 97: 576-580","DOI":"10.1161\/01.CIR.97.6.576"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Stepien O, Gogusev J, Zhu DL, Iouzalen L, Herembert T, Drueke TB, Marche P: Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol, 1998; 31: 786-793","DOI":"10.1097\/00005344-199805000-00019"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hernandez RH, Armas-Hernandez MJ, Velasco M, et al. Israili ZH, Armas-Padilla MC: Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther, 2003; 10: 409-414","DOI":"10.1097\/00045391-200311000-00006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang Y-K, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ: A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation, 1990; 82: 1940-1953","DOI":"10.1161\/01.CIR.82.6.1940"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet, 1990; 335: 1109-1113","DOI":"10.1016\/0140-6736(90)91121-P"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Motro M, Shemesh J: Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension, 2001; 37: 1410-1413","DOI":"10.1161\/01.HYP.37.6.1410"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Simon A, Gariepy J, Moyse D, Levenson J: Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation, 2001; 103: 2949-2954","DOI":"10.1161\/01.CIR.103.24.2949"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM; INSIGHT: Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension, 2003; 41: 431-436","DOI":"10.1161\/01.HYP.0000057420.27692.AD"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda A, Kawai C: Comparison of nifedipine retard with angiotensin-converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) Randomized Trial. Hypertens Res, 2004; 27: 181-191","DOI":"10.1291\/hypres.27.181"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 2000; 102: 1503-1510","DOI":"10.1161\/01.CIR.102.13.1503"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Brener SJ, Ivanc TB, Poliszczuk R, Chen M, Tuzcu EM, Hu T, Frid DJ, Nissen SE: Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J, 2006; 152: 1059-1063","DOI":"10.1016\/j.ahj.2006.07.022"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med, 2008; 359: 2417-2428","DOI":"10.1056\/NEJMoa0806182"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Jorgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E: Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol, 2000; 35: 592-599","DOI":"10.1016\/S0735-1097(99)00599-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Zanchetti A, Bond MG, Hennig M, Tang R, Hollweck R, Mancia G, Eckes L, Micheli D; ELSA Investigators: Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens, 2004; 22: 1201-1212","DOI":"10.1097\/00004872-200406000-00022"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Jukema JW, Zwinderman AH, van Boven AJ, Reiber JH, Van der Laarse A, Lie KI, Bruschke AV: Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler Thromb Vasc Biol, 1996; 16: 425-430","DOI":"10.1161\/01.ATV.16.3.425"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL: Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol, 1997; 30: 569-575","DOI":"10.1016\/S0735-1097(97)00158-7"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Nakano K, Egashira K, Ohtani K, Gang Z, Iwata E, Miyagawa M, Sunagawa K: Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice. Atherosclerosis, 2008; 196: 172-179","DOI":"10.1016\/j.atherosclerosis.2007.03.036"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Takayama M, Matsubara M, Arakawa E, Takada C, Ina Y, Hasegawa K, Yao K: Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits. Vascul Pharmacol, 2007; 46: 302-308","DOI":"10.1016\/j.vph.2006.11.004"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Cristofori P, Crivellente F, Campagnola M, Pasini AF, Garbin U, Rigoni A, Tosetti M, Turton J, Faustinelli I, Cominacini L: Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation. Int J Exp Pathol, 2004; 85: 105-114","DOI":"10.1111\/j.0959-9673.2004.00375.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Cristofori P, Lanzoni A, Quartaroli M, Pastorino AM, Zancanaro C, Cominacini L, Gaviraghi G, Turton J: The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens, 2000; 18: 1429-1436","DOI":"10.1097\/00004872-200018100-00010"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kyselovic J, Martinka P, Batova Z, Gazova A, Godfraind T: Calcium channel blocker inhibits Western-type diet-evoked atherosclerosis development in ApoE-deficient mice. J Pharmacol Exp Ther, 2005; 315: 320-328","DOI":"10.1124\/jpet.105.089847"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Willis AL, Nagel B, Churchill V, Whyte MrA, Smith DL, Mahmud I, Puppione DL: Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Atheroslcerosis, 1985; 5: 250-255","DOI":"10.1161\/01.ATV.5.3.250"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Henry PD, Bentley KI: Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest, 1981; 68: 1366-1369","DOI":"10.1172\/JCI110384"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Atkinson JB, Swift LL: Nifedipine reduces atherogenesis in cholesterol-fed heterozygous WHHL rabbits. Atherosclerosis, 1990; 84: 195-201","DOI":"10.1016\/0021-9150(90)90091-V"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Ishii N, Matsumura T, Kinoshita H, Fukuda K, Motoshima H, Senokuchi T, Nakao S, Tsutsumi A, Kim-Mitsuyama S, Kawada T, Takeya M, Miyamura N, Nishikawa T, Araki E: Nifedipine induces peroxisome proliferator-activated receptor-&gamma; activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 2010; 30: 1598-1605","DOI":"10.1161\/ATVBAHA.109.202309"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Yamashita T, Kawashima S, Ozaki M, Rikitake Y, Hirase T, Inoue N, Hirata K, Yokoyama M: A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens, 2001; 19: 451-458","DOI":"10.1097\/00004872-200103000-00013"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Anacak GY, Ustunes L, Dilsiz OY, Ergul A: Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure. Vascul Pharmacol, 2010; 53: 193-199","DOI":"10.1016\/j.vph.2010.08.003"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ: Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest, 1994; 94: 877-884","DOI":"10.1172\/JCI117409"},{"key":"39","unstructured":"39) Sakamoto W, Fujie K, Handa H: Inhibition of prostaglandin E2 and superoxide anion production in rat peritoneal macrophages by the calcium antagonists nifedipine and nisoldipine. Arzneimittelforschung, 1991; 41: 781-785"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K, Kokura S, Yoshida N, Ichikawa H, Kon T, Yoshikawa T: Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol, 2006; 546: 11-18","DOI":"10.1016\/j.ejphar.2006.07.030"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Matsubara M, Hasegawa K: Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis, 2005; 178: 57-66","DOI":"10.1016\/j.atherosclerosis.2004.08.020"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Berkels R, Breitenbach T, Bartels H, Taubert D, Rosenkranz A, Klaus W, Roesen R: Different antioxidative potencies of dihydropyridine calcium channel modulators in various models. Vascul Pharmacol, 2005; 42: 145-152","DOI":"10.1016\/j.vph.2004.11.003"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Toba H, Shimizu T, Miki S, Inoue R, Yoshimura A, Tsukamoto R, Sawai N, Kobara M, Nakata T: Calcium channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Hypertens Res, 2006; 29: 105-116","DOI":"10.1291\/hypres.29.105"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Yoshii T, Iwai M, Zhen Li Z, Chen R, Ide A, Fukunaga S, Oshita A, Mogi M, Higaki J, Masatsugu Horiuchi M: Regression of atherosclerosis by amlodipine via antiinflammatory and anti-oxidative stress actions. Hyper-tens Res, 2006; 29: 457-466","DOI":"10.1291\/hypres.29.457"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Wang N, Minatoguchi S, Chen XH, Arai M, Uno Y, Lu C, Misao Y, Nagai H, Takemura G, Fujiwara H: Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein kinase C-dependent nitric oxide in rabbits. J Cardiovasc Pharmacol, 2004; 43: 747-757","DOI":"10.1097\/00005344-200406000-00003"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Toba H, Nakagawa Y, Miki S, Shimizu T, Yoshimura A, Inoue R, Asayama J, Kobara M, Nakata T: Calcium channel blockades exhibit anti-inflammatory and anti-oxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens Res, 2005; 28: 689-700","DOI":"10.1291\/hypres.28.689"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Brovkovych V, Kalinowski L, Muller-Peddinghaus R, Malinski T: Synergistic Antihypertensive Effects of Nifedipine on Endothelium : Concurrent Release of NO and Scavenging of Superoxide. Hypertension, 2001; 37: 34-39","DOI":"10.1161\/01.HYP.37.1.34"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol, 1999; 31: 275-281","DOI":"10.1006\/jmcc.1998.0867"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, Salvetti A: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension, 2001; 37: 943-948","DOI":"10.1161\/01.HYP.37.3.943"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Rachmani R, Levi Z, Zadok BS, Ravid M: Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther, 2002; 72: 302-307","DOI":"10.1067\/mcp.2002.127110"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Witztum JL: The oxidation hypothesis of atherosclerosis. Lancet, 1994; 344: 793-795","DOI":"10.1016\/S0140-6736(94)92346-9"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem, 1997; 272: 20963-20966","DOI":"10.1074\/jbc.272.34.20963"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Mason RP: Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis, 2002; 165: 191-199","DOI":"10.1016\/S0021-9150(01)00729-8"},{"key":"54","unstructured":"54) Kramsch DM, Sharma RC: Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent. J Hum Hypertens, 1995; 9(suppl 1): S3-S9"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Chen L, Haught WH, Yang B, Saldeen TGP, Parthasarathy S, Mehta JL: Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol, 1997; 30: 569-575","DOI":"10.1016\/S0735-1097(97)00158-7"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol, 1999; 31: 275-281","DOI":"10.1006\/jmcc.1998.0867"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Libby P: Inflammation in atherosclerosis. Nature, 2002; 420: 868-874","DOI":"10.1038\/nature01323"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol, 2004; 43: 724-730","DOI":"10.1097\/00005344-200405000-00016"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Matsui T, Yamagishi S, Nakamura K, Inoue H: Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells. J Int Med Res, 2006; 34: 671-675","DOI":"10.1177\/147323000603400613"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Costa S, Zimetti F, Pedrelli M, Cremonesi G, Bernini F: Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages. Pharmacol Res, 2010; 62: 265-270","DOI":"10.1016\/j.phrs.2010.03.004"},{"key":"61","unstructured":"61) Yamagishi S, Inagaki Y, Kikuchi S: Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp Clin Res, 2003; 29: 147-152"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Wu L, Iwai M, Li Z, Li JM, Mogi M, Horiuchi M: Nifedipine inhibited angiotensin II-induced monocyte chemoattractant protein 1 expression: involvement of inhibitor of nuclear factor &kappa;B kinase and nuclear factor &kappa;B-inducing kinase. J Hypertens, 2006; 24: 123-130","DOI":"10.1097\/01.hjh.0000198031.30095.d1"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Matsubara M, HasegawaK: Effects of benidipine, a dihydropyridine-Ca<sup>2+<\/sup> channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. Eur J Pharmacol, 2004; 498: 303-314","DOI":"10.1016\/j.ejphar.2004.07.086"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K, Kokura S, Yoshida N, Ichikawa H, Kon T, Yoshikawa T: Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol, 2006; 546: 11-18","DOI":"10.1016\/j.ejphar.2006.07.030"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Takahashi K, Shimokado K, Yoshida M: SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition. Eur J Pharmacol, 2006; 552: 162-169","DOI":"10.1016\/j.ejphar.2006.09.028"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Cominacini L, Pasini AF, Pastorino AM, Garbin U, Davoli A, Rigoni A, Campagnola M, Tosetti ML, Rossato P, Gaviraghi G: Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-&alpha; on endothelial cells. J Hyper-tens, 1999; 17: 1837-1841","DOI":"10.1097\/00004872-199917121-00009"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Cominacini L, Garbin U, Fratta Pasini A, Paulon T, Davoli A, Campagnola M, Marchi E, Pastorino AM, Gaviraghi G, Lo Cascio V: Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens, 1997; 15: 1633-1640","DOI":"10.1097\/00004872-199715120-00065"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Li Q, Verma IM: NF-&kappa;B regulation in the immune system. Nat Rev Immunol, 2002; 2: 725-734","DOI":"10.1038\/nri910"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Agrawal A, Cha-Molstad H, Samols D, Kushner I: Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT\/enhancer binding protein beta (C\/EBP&beta;) and Rel p50. J Immunol, 2001; 166: 2378-2384","DOI":"10.4049\/jimmunol.166.4.2378"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Ferran C, Millan MT, Csizmadia V, Cooper JT, Brostjan C, Bach FH, Winkler H: Inhibition of NF-&kappa;B by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem Biophys Res Commun, 1995; 214: 212-223","DOI":"10.1006\/bbrc.1995.2277"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Wang T, Zhang X, Li JJ: The role of NF-&kappa;B in the regulation of cell stress responses. Int Immunopharmacol, 2002; 2: 1509-1520","DOI":"10.1016\/S1567-5769(02)00058-9"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Vlahopoulos S, Boldogh I, Casola A, Brasier AR: Nuclear factor-&kappa;B-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation. Blood, 1999; 94: 1878-1889","DOI":"10.1182\/blood.V94.6.1878.418k03_1878_1889"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Matsumori A, Nunokawa Y, Sasayama S: Nifedipine inhibits activation of transcription factor NF-&kappa;B. Life Sci, 2000; 67: 2655-2661","DOI":"10.1016\/S0024-3205(00)00849-3"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Hayashi M, Yamaji Y, Nakazato Y, Saruta T: The effects of calcium channel blockers on nuclear factor &kappa;B activation in the mesangium cells. Hypertens Res, 2000; 23: 521-525","DOI":"10.1291\/hypres.23.521"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Oiso Y, Nakashima N: Nilvadipine inhibits nuclear factor-&kappa;B-dependent transcription in hepatic cells. Clinica Chimica Acta, 2004; 350: 151-157","DOI":"10.1016\/j.cccn.2004.07.012"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Szabo C, Thiemermann C, Vane JR: Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Biochem Biophys Res Commun, 1993; 196: 825-830","DOI":"10.1006\/bbrc.1993.2323"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Hattori Y, Kasai K, So S, Hattori S, Banba N, Shimoda S: Effects of calcium channel antagonists on the induction of nitric oxide synthase in cultured cells by immunostimulants. Life Sci, 1995; 57: 1833-1840","DOI":"10.1016\/0024-3205(95)02163-D"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Takayama M, Yao K, Wada M: The dihydropyridine calcium channel blocker benidipine prevents lysophosphatidylcholine-induced endothelial dysfunction in rat aorta. J Biomed Sci, 2009; 16: 57-66","DOI":"10.1186\/1423-0127-16-57"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Sugano M, Tsuchida K, Makino N: Nifedipine prevents apoptosis of endothelial cells induced by oxidized low-density lipoproteins. J Cardiovasc Pharmacol, 2002; 40: 146-152","DOI":"10.1097\/00005344-200207000-00018"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Ando H, Nakanishi K, Shibata M, Hasegawa K, Yao K, Miyaji H: Benidipine, a dihydropyridine-Ca<sup>2+<\/sup> channel blocker, increases the endothelial differentiation of endothelial progenitor cells in vitro. Hypertens Res, 2006; 29: 1047-1054","DOI":"10.1291\/hypres.29.1047"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Lusis AJ: Atherosclerosis. Nature, 2000; 407: 233-241","DOI":"10.1038\/35025203"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993; 362: 801-809","DOI":"10.1038\/362801a0"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Arakawa E, Hasegawa K: Benidipine, a calcium channel blocker, regulates proliferation and phenotype of vascular smooth muscle cells. J Pharmacol Sci, 2006; 100: 149-156","DOI":"10.1254\/jphs.FPJ05024X"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Corsini A, Bonfatti M, Quarato P, Accomazzo MR, Raiteri M, Sartani A, Testa R, Nicosia S, Paoletti R, Fumagalli R: Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol, 1996; 28: 687-694","DOI":"10.1097\/00005344-199611000-00012"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Absher MP, Baldor L, Warshaw DM: Effects of nitrendipine on growth activity in cultured vascular smooth muscle cells. J Cardiovasc Pharmacol, 1988; 12 Suppl 4: S104-S106","DOI":"10.1097\/00005344-198806124-00022"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Ko Y, Totzke G, Graack GH, Heidgen FJ, Meyer zu Brickwedde MK, Dusing R, Vetter H, Sachinidis A: Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells. J Hypertens, 1993; 11: 1171-1178","DOI":"10.1097\/00004872-199311000-00003"},{"key":"87","unstructured":"87) Hirata Y, Eguchi S, Tsujino M: Effects of manidipine on DNA and protein syntheses in cultured vascular smooth muscle and endothelial cells and on proto-oncogene expression. Blood Press Suppl, 1992; 3: 30-35"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Ide S, Kondoh M, Satoh H, Karasawa A: Anti-proliferative effects of benidipine hydrochloride in porcine cultured vascular smooth muscle cells and in rats subjected to balloon catheter-induced endothelial denudation. Biol Pharm Bull, 1994; 17: 627-631","DOI":"10.1248\/bpb.17.627"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Bernini F, Corsini A, Raiteri M, Soma MR, Paoletti R: Effects of lacidipine on experimental models of atherosclerosis. J Hypertens Suppl, 1993; 11: S61-S66","DOI":"10.1097\/00004872-199303001-00011"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Hu WY, Fukuda N, Su JZ, Kanmatsuse K: Effects of the L- and N-type calcium channel blocker cilnidipine on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol, 2001; 38: 450-459","DOI":"10.1097\/00005344-200109000-00013"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Tsukada T, Rosenfeld M, Ross R, Gown AM: Immunocytochemical analysis of cellular components in atherosclerotic lesions. Use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis, 1986; 6: 601-613","DOI":"10.1161\/01.ATV.6.6.601"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Schwartz SM, Campbell GR, Campbell JH: Replication of smooth muscle cells in vascular disease. Circ Res, 1986; 58: 427-444","DOI":"10.1161\/01.RES.58.4.427"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Canavesi M, Baldini N, Leonardi A, Sironi G, Bellosta S, Bernini F: <i>In vitro<\/i> inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol, 2004; 44: 416-422","DOI":"10.1097\/01.fjc.0000139448.56713.3d"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Dushkin MI, Schwartz YS: Effect of verapamil and nifedipine on cholesteryl ester metabolism and low-density lipoprotein oxidation in macrophages. Biochem Pharmacol, 1995; 49: 389-397","DOI":"10.1016\/0006-2952(94)00407-D"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Bernini F, Bellosta S, Didoni G, Fumagalli R: Calcium antagonists and cholesteryl ester metabolism in macrophages. J Cardiovasc Pharmacol, 1991; 18: S42-S45","DOI":"10.1097\/00005344-199118101-00007"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Bernini F, Canavesi M, Bernardini E, Scurati N, Bellosta S, Fumagalli R: Effect of lacidipine on cholesterol esterification: <i>in vivo<\/i> and in vitro studies. Br J Pharmacol, 1997; 122: 1209-1215","DOI":"10.1038\/sj.bjp.0701469"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Etingin OR, Hajjar DP: Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its anti-atherogenic effect. J Clin Invest, 1985; 75: 1554-1558","DOI":"10.1172\/JCI111860"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Etingin OR, Hajjar DP: Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue. Circ Res, 1990; 66: 185-190","DOI":"10.1161\/01.RES.66.1.185"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Hasegawa K, Wakino S, Kanda T, Yoshioka K, Tatematsu S, Homma K, Takamatsu I, Sugano N, Hayashi K: Divergent action of calcium channel blockers on ATP-binding cassette protein expression. J Cardiovasc Pharmacol, 2005; 46: 787-793","DOI":"10.1097\/01.fjc.0000187976.60262.bf"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Suzuki S, Nishimaki-Mogami T, Tamehiro N, Tamehiro M, Inoue K, Arakawa R, Abe-Dohmae S, Tanaka AR, Ueda K, Yokoyama S: Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via liver X receptor-independent mechanism. Arterioscler Thromb Vasc Biol, 2004; 24: 519-525","DOI":"10.1161\/01.ATV.0000117178.94087.ba"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF: The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest, 1999; 104: R25-R31","DOI":"10.1172\/JCI8119"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Dollery CM, Mcewan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res, 1995; 77: 863-868","DOI":"10.1161\/01.RES.77.5.863"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Bellosta S, Canavesi M, Favari E, Cominacini L, Gaviraghi G, Fumagalli R, Paoletti R, Bernini F: Lacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. J Pharmacol Exp Ther, 2001; 296: 736-743","DOI":"10.1016\/S0022-3565(24)38810-X"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Ikeda U, Hojo Y, Ueno S, Arakawa H, Shimada K: Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells. J Cardiovasc Pharmacol, 2000; 35: 887-890","DOI":"10.1097\/00005344-200006000-00009"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Roth M, Eickelberg O, Kohler E, Erne P, Block LH: Ca<sup>2+<\/sup> channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A, 1996; 93: 5478-5482","DOI":"10.1073\/pnas.93.11.5478"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Anacak GY, Ustunes L, Dilsiz OY, Ergul A: Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure. Vascul Pharmacol, 2010; 53: 193-199","DOI":"10.1016\/j.vph.2010.08.003"},{"key":"107","unstructured":"107) Spiegelman BM: Peroxisome proliferator-activated receptor &gamma;: A key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res, 1997; 2: 457-464"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor &gamma; and promotes adipocyte differentiation. Cell, 1995; 83: 813-819","DOI":"10.1016\/0092-8674(95)90194-9"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Ricote M Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-&gamma; is a negative regulator of macrophage activation. Nature, 1998; 391: 79-82","DOI":"10.1038\/34178"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B: Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res, 1999; 85: 394-402","DOI":"10.1161\/01.RES.85.5.394"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor &gamma; activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res, 1998; 83: 1097-1103","DOI":"10.1161\/01.RES.83.11.1097"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophage in human atheroma contain PPAR&gamma;: Differentiation-dependent peroxisomal proliferator-activated receptor &gamma; (PPAR&gamma;) expression and reduction of MMP-9 activity through PPAR&gamma; activation in mononuclear phagocytes in vitro. Am J Pathol, 1998; 153: 17-23","DOI":"10.1016\/S0002-9440(10)65540-X"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK: Expression of the peroxisome proliferator-activated receptor &gamma; (PPAR&gamma;) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A, 1998; 95: 7614-7619","DOI":"10.1073\/pnas.95.13.7614"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Francis GA, Annicotte JS, Auwerx J: PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol, 2003; 3: 186-191","DOI":"10.1016\/S1471-4892(03)00014-6"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK: Peroxisome proliferator-activated receptor &gamma; ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest, 2000; 106: 523-531","DOI":"10.1172\/JCI10370"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR&alpha;, &beta;\/&delta;, and &gamma;. J Clin Invest, 2004; 114: 1564-1576","DOI":"10.1172\/JCI18730"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N: Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol, 2001; 21: 372-377","DOI":"10.1161\/01.ATV.21.3.372"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2001; 21: 365-371","DOI":"10.1161\/01.ATV.21.3.365"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Claudel T, Leibowitz MD, Fievet C Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci U S A, 2001; 98: 2610-2615","DOI":"10.1073\/pnas.041609298"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet, 2005; 366: 1279-289","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121) Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, 2006; 296: 2572-2581","DOI":"10.1001\/jama.296.21.joc60158"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122) Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA, 2008; 299: 1561-1573","DOI":"10.1001\/jama.299.13.1561"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123) Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, Sawada T, Kawamori H, Kato H, Miyoshi N, Hirata K: Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J, 2009; 73: 343-351","DOI":"10.1253\/circj.CJ-08-0699"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124) Hashimoto R, Umemoto S, Guo F, Umeji K, Itoh S, Kishi H, Kobayashi S, Matsuzaki M: Nifedipine activates PPAR&gamma; and exerts antioxidative action through Cu\/ZnSOD independent of blood-pressure lowering in SHRSP. J Atheroscler Thromb, 2010; 17: 785-795","DOI":"10.5551\/jat.4556"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125) Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S: Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-&gamma; activation. Biochem Biophys Res Commun, 2009; 385: 269-272","DOI":"10.1016\/j.bbrc.2009.05.061"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126) Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M: Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine. Hypertension, 2008; 51: 528-533","DOI":"10.1161\/HYPERTENSIONAHA.107.101634"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127) Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M: Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther, 2006; 319: 1081-1087","DOI":"10.1124\/jpet.106.108894"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128) Kosegawa I, Inaba M, Morita T, Awata T, Katayama S: Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hyper-tens,1998; 20: 751-761","DOI":"10.3109\/10641969809052117"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/19\/8\/19_12450\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T13:59:12Z","timestamp":1743170352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/19\/8\/19_12450\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":128,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.12450","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}